Beryl Drugs Limited (BOM:524606)

Beryl Drugs Statistics

Total Valuation

Beryl Drugs has a market cap or net worth of INR 107.57 million. The enterprise value is 140.16 million.

Market Cap	107.57M
Enterprise Value	140.16M

Important Dates

The next estimated earnings date is Friday, August 8, 2025.

Earnings Date	Aug 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Beryl Drugs has 5.07 million shares outstanding. The number of shares has increased by 0.13% in one year.

Current Share Class	5.07M
Shares Outstanding	5.07M
Shares Change (YoY)	+0.13%
Shares Change (QoQ)	-0.39%
Owned by Insiders (%)	40.98%
Owned by Institutions (%)	n/a
Float	2.99M

Valuation Ratios

The trailing PE ratio is 18.61.

PE Ratio	18.61
Forward PE	n/a
PS Ratio	0.51
PB Ratio	1.13
P/TBV Ratio	1.13
P/FCF Ratio	23.82
P/OCF Ratio	4.08
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.31, with an EV/FCF ratio of 31.04.

EV / Earnings	24.21
EV / Sales	0.66
EV / EBITDA	5.31
EV / EBIT	10.04
EV / FCF	31.04

Financial Position

The company has a current ratio of 2.10, with a Debt / Equity ratio of 0.43.

Current Ratio	2.10
Quick Ratio	1.46
Debt / Equity	0.43
Debt / EBITDA	1.54
Debt / FCF	9.02
Interest Coverage	2.63

Financial Efficiency

Return on equity (ROE) is 6.28% and return on invested capital (ROIC) is 6.32%.

Return on Equity (ROE)	6.28%
Return on Assets (ROA)	5.21%
Return on Invested Capital (ROIC)	6.32%
Return on Capital Employed (ROCE)	11.97%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	1.26
Inventory Turnover	6.04

Taxes

In the past 12 months, Beryl Drugs has paid 2.87 million in taxes.

Income Tax	2.87M
Effective Tax Rate	33.13%

Stock Price Statistics

The stock price has decreased by -33.46% in the last 52 weeks. The beta is 0.15, so Beryl Drugs's price volatility has been lower than the market average.

Beta (5Y)	0.15
52-Week Price Change	-33.46%
50-Day Moving Average	20.26
200-Day Moving Average	28.26
Relative Strength Index (RSI)	49.65
Average Volume (20 Days)	1,453

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Beryl Drugs had revenue of INR 211.46 million and earned 5.79 million in profits. Earnings per share was 1.14.

Revenue	211.46M
Gross Profit	103.62M
Operating Income	13.95M
Pretax Income	8.66M
Net Income	5.79M
EBITDA	26.41M
EBIT	13.95M
Earnings Per Share (EPS)	1.14

Balance Sheet

The company has 8.14 million in cash and 40.74 million in debt, giving a net cash position of -32.59 million or -6.43 per share.

Cash & Cash Equivalents	8.14M
Total Debt	40.74M
Net Cash	-32.59M
Net Cash Per Share	-6.43
Equity (Book Value)	95.04M
Book Value Per Share	18.77
Working Capital	47.45M

Cash Flow

In the last 12 months, operating cash flow was 26.37 million and capital expenditures -21.85 million, giving a free cash flow of 4.52 million.

Operating Cash Flow	26.37M
Capital Expenditures	-21.85M
Free Cash Flow	4.52M
FCF Per Share	0.89

Margins

Gross margin is 49.00%, with operating and profit margins of 6.60% and 2.74%.

Gross Margin	49.00%
Operating Margin	6.60%
Pretax Margin	4.09%
Profit Margin	2.74%
EBITDA Margin	12.49%
EBIT Margin	6.60%
FCF Margin	2.14%

Dividends & Yields

Beryl Drugs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.13%
Shareholder Yield	n/a
Earnings Yield	5.38%
FCF Yield	4.20%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	6